Metropolis Healthcare Shines With Robust Q2 Revenue Growth and Expanding Profit Margins

The quarter ended September 30, 2025, saw Metropolis Healthcare Ltd deliver a strong financial performance, underpinned by consolidated revenue growth and profitability advances.

 

Key Highlights of the Quarter

 

Revenue from operations rose 13.4% year-on-year to INR 350 crore, reflecting a healthy uptick fueled by expanding patient and test volumes.

 

Patient volumes increased by 7%, while test volumes grew 8%, boosting revenue per patient by 6%.

 

EBITDA rose by 22.2% to INR 92 crore, with margins improving to 25.7% from the prior year's 24.2%.

 

Profit after tax surged 31% to INR 47 crore, lifting net margins to 13.4%, up 180 basis points year-over-year.

 

The business-to-consumer segment grew 21% driven by same-store growth of 12% and addition of over 400 new centers, accounting for 56% of revenue.

 

Business-to-business revenues rose 13%, contributing 35% of total revenue.

 

Specialty and TruHealth segments recorded significant growth of 16% and 23% respectively.

 

Performance Drivers and Outlook

Metropolis Healthcare’s growth was propelled by broad-based volume expansion, geographic network enlargement, and improved revenue per patient. The company continues strategic focus on advancing testing capabilities and capturing expansion opportunities in tier 3 cities. Management foresees sustained growth supported by its strong footprint and pipeline of initiatives including potential mergers and acquisitions.

 

This results announcement reflects solid operational execution and positions Metropolis Healthcare for durable, long-term value creation for shareholders.

 

Sources: Metropolis Healthcare official releases, Moneycontrol, NDTVProfit, Business Standard, MarketsMojo